[BioSante Letterhead]
December 17, 2009
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
Mail Stop 4720
Re: BioSante Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2008
Definitive Proxy Statement on Schedule 14A
Form 8-K dated October 14, 2009
File Number: 001-31812
Dear Mr. Rosenberg:
As a follow-up to my telephone conversation with Dana Hartz on December 16, 2009, this letter is to confirm that the Staff of the Division of Corporation Finance has approved the request of BioSante Pharmaceuticals, Inc. to extend the due date by no later than January 15, 2010, for our response to your comment letter dated December 15, 2009, File No. 001-31812.
Thank you very much for providing us this extension of time.
Sincerely, |
|
|
|
/s/ Phillip B. Donenberg |
|
|
|
Phillip B. Donenberg |
|
Chief Financial Officer, Treasurer and Secretary |
|
cc: Dana Hartz, Staff Accountant
